Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Meta-Analysis Links Diabetes to Increased Blood Cancer Risk

By BiotechDaily International staff writers
Posted on 21 Jun 2012
Print article
According to a new, worldwide meta-analysis, patients with type 2 diabetes have a significantly increased risk of developing certain types of blood cancers.

A collaborative study led by researchers at The Miriam Hospital (Providence, RI, USA) analyzed 26 (13 case-control and 13 cohort) published observational studies that had evaluated the association between diabetes mellitus type 2 and the incidence of lymphoma, leukemia, and myeloma. The meta-analysis included more than 17,000 cases of type 2 diabetes and blood cancer worldwide. The researchers concluded that patients with type 2 diabetes have about 20% increased risk of developing leukemia, myeloma, and non-Hodgkin lymphoma, as well as a subtype of non-Hodgkin lymphoma known as peripheral T-cell lymphoma. They did not find any associations with Hodgkin lymphoma. The findings suggest type 2 diabetes could be associated with approximately 5% of all incidents of leukemia, myeloma, and non-Hodgkin lymphoma.

The researchers also found that the risk of lymphoma, leukemia, and myeloma appears to differ depending on the geographic region of the original report. For example, the risk of non-Hodgkin lymphoma was higher in Asia and Europe, while there was an increased leukemia risk in the United States and Asia.

“When you consider that [millions of people have type 2 diabetes and that millions more are still likely to develop it], a 20% increased risk of blood cancer is quite significant,” noted lead author Jorge Castillo, MD, a hematologist-oncologist with The Miriam Hospital. He added, “It’s important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise; so by preventing the onset of type 2 diabetes, we could also prevent blood cancer.” Dr. Castillo and colleagues suggested that, in addition to studying antidiabetic therapy, future research should focus particularly on evaluating roles of behavioral factors such as obesity, physical activity, dietary habits, and smoking, which have been linked to both diabetes and cancer.

The findings, published online May 24, 2012, in the American Society of Hematology journal Blood, add to the growing evidence base linking diabetes and certain types of cancer.

Related Links:

The Miriam Hospital



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.